Ling-Yu Kuan

Suggest Changes
Learn More
Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen(More)
  • 1